Acolbifene

Summary

Acolbifene (CHEMBL68055) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 457.6 Da · C29H31NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL68055
Name	Acolbifene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	155435
Molecular formula	C29H31NO4
Molecular weight	457.6
InChIKey	DUYNJNWVGIWJRI-LJAQVGFWSA-N

SMILES: CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O

IUPAC name: (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol

Also known as: Acolbifene, Acolbifeno, Em-652, SCH-57068, SCH57068, ACOLBIFENE

Parent form; salt/anhydrous children: CHEMBL2105965

Patent coverage: 425 distinct patent families (1,159 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,092 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Estrogen receptor.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	10.82	Ki	0.01	nM	CHEMBL_ACT_1292156
ESR1	10.38	Ki	0.04	nM	CHEMBL_ACT_1292151
ESR1	10.33	Ki	0.05	nM	CHEMBL_ACT_1292147
ESR1	10.16	Ki	0.07	nM	CHEMBL_ACT_1292153
ESR1	10.12	Ki	0.08	nM	CHEMBL_ACT_1292149
ESR1	10.05	Ki	0.09	nM	CHEMBL_ACT_1292158
ESR1	9.85	IC50	0.14	nM	CHEMBL_ACT_1292155
ESR1	9.26	IC50	0.55	nM	CHEMBL_ACT_1292157

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01452373	PHASE3	COMPLETED	Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).